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1. Introduction
Genitourinary cancer comprises kidney, prostate, bladder, upper urinary tract and testis
neoplasms. The incidence rates of them vary between 15 and 1.5% in developed countries.
The epidemiology of genitourinary cancer varies depend on the organ. Prostate cancer is the
most common solid neoplasm in males (15%) and renal cell neoplasm involves since 3% of all
adult cancers. Urothelial carcinomas are the fourth most common tumors, after prostate, breast
(females), lung and colorectal cancer. In particular, bladder cancer is the 9th most common
cancer diagnosis worldwide. Testicular cancer is the less common genitourinary cancer that
represents between 1% and 1.5% of male neoplasms [1].
The wide range of treatments against these diseases comprises surgery, radiotherapy and
chemotherapy. Radiotherapy is used to treat localized and locally-advanced prostate cancer
even with curative intent. Also radiotherapy is used to prophylactic treatment in seminoma‐
tous testis cancer to avoid para-aortic or iliac lymphatic relapses. In bladder cancer, radio‐
therapy is used as a palliative treatment against hematuria. Radiotherapy does not play an
important role in kidney cancer, only it is used to treat selected metastasis cases.
Chemoteraphy in prostate cancer (Taxanes) is reserved for the treatment of metastatic
castration refractory prostate cancer. At renal cell carcinoma, Tyrosine kinase inhibitors or
Mammalian target of rapamycin (mTOR) inhibitors should be considered as first- or second-
line treatment for metastatic disease. Cisplatin-based chemoteraphy in bladder cancer is
considered as a neoadyuvant or adyuvant treatment before and after cystectomy if there is
suspicion or evidence of lymph node metastasis. Carboplatin-based chemoteraphy is used to
treat several seminomatous testis neoplasms stages after orchiectomy. Cisplatin, eposide and
bleomycin or eposide and cisplatin combinations are used to treat non-seminomatous testis
© 2013 Antonio; licensee InTech. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
neoplasm combined or not to retroperitoneal lymph node nerve-sparring surgery and also in
metastatic cases.
More and more genitourinary cancers are diagnosed in localized stages, making surgical
treatment possible [1]. Since Bill Schuessler performed the first laparoscopic lymphadenecto‐
my in a patient with localized prostate cancer (October 1989), Urologists have acquired
technology advances applied to laparoscopic surgery. In the last decades, those advances have
made a minimally invasive approach to treat these cancers easier. That has caused that today
laparoscopy approach is the technique of choice in the surgical treatment of some localized
genitourinary cancers [2].
According the PUBMED database, there is an increase in the publication of articles dealing
with the laparoscopic treatment. In the last 5 years almost 10% of those articles referring
specifically to laparoscopic surgery. (Graphic 1).
 
 
 
Figure 1. Evolution of published articles on laparoscopic surgery in PUBMED (MESH database).
Today there is a trend towards minimally invasive surgery but it is necessary to establish
whether the outcomes of competing treatment options (open Vs laparoscopy) are comparable,
focusing in postoperative morbidity and oncologic outcomes.
This chapter gives a summary of laparoscopic treatment reviewing the indication, morbidity
and oncologic and functional results compared to conventional surgery for each of the listed
cancers, providing a general overview.
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Table 1. Kidney. Primary tumor stage (T) [41].
2. Renal cancer
Renal cell carcinoma (RCC) accounts for 2-3% of all adult cancers. More than 50% are diagnosed
at a localized stage (pT1-pT2) (Table 2). Open radical or partial nephrectomy has been the
standard curative intervention for localized RCC for the past five decades, laparoscopy also
being an alternative in RCC with renal vein tumor thrombus (pT3a) (Table 2). With the new
minimally invasive approaches, laparoscopic radical or partial nephrectomy has become an
acceptable alternative to open surgery [3,4]
Table 2. Prostate. Pathologic tumor stage (pT) [42].
2.1. Morbidity and functional outcomes
In comparison with open radical nephrectomy, laparoscopic procedure offers less morbidity
(back pain and postoperative blood loss) and hospital stay [3].
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Nephron-sparing surgery offers better preservation of renal function than radical nephrecto‐
my and lower risk of cardiac death but efforts should be made to limit the renal function loss
associated with surgery for localized renal masses regarding transient ischemia at surgery,
because warm ischemia time seems to be the most important independent variable for
predicting renal damage. This damage occurs within the third postoperative month [5,6].
Laparoscopic nephron-sparing surgery provides less blood loss, median operative time,
median analgesic requirement, hospital stay and median convalescence time, compared to
open partial nephrectomy. But it means more major intra-operative complications (5% Vs 0%),
renal / urological complications (11% Vs 2%) and warmer ischemia time [7].
2.2. Oncologic outcomes
2.2.1. Localised renal cell carcinoma
There are no randomised studies assessing oncological outcomes. Papers published found
similar oncological outcomes; the 5 year overall survival for laparoscopic versus open radical
nephrectomy was 87.8% and 88.7%, respectively. There was no evidence of any difference in
cancer-specific and recurrence-free survival at 5 year reported in the studies [4].
With respect to the approach at localized RCC, few randomized studies compared retroperi‐
toneal with transperitoneal radical nephrectomy. Both of them were found to have a similar
oncological outcomes and no incidences of positive surgical margins were reported [4,8].
When laparoscopic partial nephrectomy was compared to open partial nephrectomy, a
database review of Lane et al. noted an overall survival benefit increase in laparoscopic versus
open partial nephrectomy when adjusting for age, gender, race, Charlson index, tumor size,
hypertension and the predicted risk of recurrence at 5 year in those patients with a minimum
of 1 year follow-up, but there were no differences in 3 year cancer-specific survival, 5 year
overall survival and 7 year follow-up (92.7% Vs 95.6% in cancer-specific survival respectively).
This study described a lower risk of all-cause death in the laparoscopic group [9]. The same
results were described by Gill et al. and Marszalek et al; both of them did not find differences
in the recurrence patterns between both groups [10,11].
There has been controversy about the suitable tumor size to perform a laparoscopy nephron-
sparing intervention. A cut-off of 4cm has been recommended but some authors have argued
that partial nephrectomy is feasible up to 7cm with no reduction in oncologic outcomes. In this
view Simmons et al. published a database review for tumors larger than 4cm treated by
laparoscopic partial nephrectomy versus laparoscopic radical nephrectomy. There was no
difference in estimated overall survival (74% versus qué), cancer-specific survival and
recurrence-free survival rates (both 81% versus qué) [4,12].
In addition to size, other factors about renal mass anatomy such as growth pattern (endo-/
meso-/exophytic) and location (central/hilar/peripheral, anterior/posterior, lateral/medial,
polar) are important to consider a nephron-sparing surgery. It is more feasible if tumor is
placed in a peripheral/polar/posterior site, for example [13].
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2.2.2. Locally-advanced renal cell carcinoma
Laparoscopic surgery has been extended to patients with renal cell carcinoma associated with
limited local invasion and lymph node metastases or in the presence of renal vein and inferior
vena cava thrombi. In well-selected patients with metastatic renal cell carcinoma, laparoscopic
cytoreductive nephrectomy can be performed safely, with less morbidity than open nephrec‐
tomy [14]. Laparoscopic nephrectomy in metastatic RCC should be recommended to those
patients with a good performance status before oncological treatment. The expanding
indications for laparoscopic radical nephrectomy are: larger tumors (>7cm), renal vein tumor
thrombus, cytoreductive nephrectomy and limited locally invasive tumors into psoas or
diaphragm muscle. This technique must be performed in selected patients [8,15]..
2.3. Conclusions
For localized renal cancer, laparoscopic radical nephrectomy is the approach of choice because
it offers less morbidity than open nephrectomy and both of them achieve similar oncological
outcomes, such as survival and recurrence rates. There are no differences between transperi‐
toneal and retroperitoneal approach.
When renal tumors are ≤ 4cm laparoscopic partial nephrectomy is a good choice but location
of tumor is also important to perform surgery. In these cases, partial nephrectomy improves
survival.
Laparoscopic partial nephrectomy shows no improvement than laparoscopic radical neph‐
rectomy when renal tumors are > 4cm but laparoscopic approach is a correct choice depending
on surgeon skill and renal mass anatomy.
For locally-advanced renal cancer, laparoscopic radical nephrectomy is a technically feasible
approach in carefully selected patients with a good performance status. Optimal patient
selection, large laparoscopic experience and multidisciplinary support are the more important
elements for a safe application of this approach.
Additional data are needed because most of the studies are retrospective and is necessary to
improve methodological quality.
3. Prostate cancer
Prostate cancer (PCa) is one of the most common solid neoplasm in male. In Europe it has an
incidence rate of 214 cases per 1000 men, outnumbering lung and colorectal cancer. PCa is
currently the second most common cause of cancer death in men [16].
Currently, there is an increase in the diagnosis of PCa, concretely clinically localized prostate
cancer (table 3). Radical prostatectomy is a common treatment for these patients, who have
also life expectancy more than 10 years [17]. Radical prostatectomy has been associated with
complications and sequel, including intraoperative blood loss, postoperative urinary inconti‐
nence and erectile dysfunction. With the intent of reducing the invasiveness of traditional open
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retropubic approach and complications, urologists have developed the laparoscopic techni‐
que, which represents a different perspective of surgical anatomy that implies an important
learning curve [17].
Table 3. Urothelium. Primary tumor stage (T) [43,44].
3.1. Morbidity and functional outcomes
Several studies demonstrate that operative time of laparoscopic approach was significantly
longer than open retropubic approach, but laparoscopic approach showed less blood loss and
lower transfusion rates than the open procedure [17,18]. The overall complications rate was
significantly lower in those patients undergoing laparoscopy radical prostatectomy [17,18].
A single, nonrandomized prospective trial compared retropubic radical prostatectomy with
laparoscopy prostatectomy, demonstrating that tissue damage was significantly lower in
laparoscopic approach. Specifically, plasmatic levels of IL-6 and C-reactive protein were lower
at the end of procedure, 12 hours later and 24 hours later [17].
In relation to postoperative pain (measured by validated 10-point visual analogue scale),
laparoscopic radical prostatectomy with retroperitoneal approach seems to be the best
tolerated technique during the first five postoperative days, compared with transperitoneal
and open approaches [19]. Considering the studies reporting the requirements of morphine
sulfate equivalent during the postoperative course, it seems to be no differences between open
and laparoscopic approach [17].
In the published comparative studies, catheterization times and hospital stay were lower in
laparoscopic approach [17]. Full recovery was faster in laparoscopic than open approach [18].
Laparoscopic radical prostatectomy had a lower rate of anastomotic strictures compared to
open retropubic prostatectomy [17].
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About urinary incontinence and erectile function, cumulative analysis of the available data
suggest that continence rates and erectile function after open or laparoscopic approach are similar
[17,18]. The same occurs when quality of life after surgery was analyzed in both groups [17].
3.2. Oncologic outcomes
With regard to the oncologic outcomes, in the published comparative studies, the main item
evaluated was the surgical margins. Guazzoni et al published the study with the highest level
of evidence, demonstrating that the positive surgical margins rates obtained after open
retropubic radical prostatectomy and laparoscopic radical prostatectomy were overlapping
[20]. In addition, when the data were stratified by the pathologic stages, there were no
differences between the two procedures [17,21].
3.3. Conclusions
Laparoscopy radical prostatectomy implies an important learning curve to achieve good
functional and oncologic outcomes. Currently, laparoscopy approach is better than open
approach in terms of perioperative and early postoperative outcomes such as: blood loss,
transfusion requirements, tissue damage, postoperative pain (only the first few days), hospital
stay, and full recovery time.
Several studies showed a lower rate of anastomotic stricture after laparoscopic approach.
At laparoscopic approach, the surgeon skill is very important to perform good bladder neck
preservation, paraurethral dissection and nerve sparing surgery (when it is possible), to obtain
good functional results. In general, laparoscopic approach does not offer more advantages in
urinary continence or erectile function after surgery and the oncologic outcomes, compared
to open approach, are similar.
There were no differences between retroperitoneal and transperitoneal approach [22].
It is necessary more prospective studies, as well randomised series to analyze oncologic
outcomes and morbidity comparing more than retroperitoneal or transperitoneal approach at
the laparoscopic procedure, as well as the addition of lymphadenectomy.
It is likely that the most critical issue in surgical treatment of localized prostate cancer is the selection
of the best surgical technique fitted to the surgeon, rather than only the surgical approach.
4. Urothelial cancer: Bladder and upper urinary tract
4.1. Bladder cancer
Bladder cancer is the 9th most common cancer diagnosis worldwide, with an estimated male:
female ratio of 3.8:1.0. At the initial diagnosis of bladder cancer approximately 30% has muscle-
invasive disease [23].
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Muscle invasive urothelial bladder cancer is a highly aggressive disease in which surgical
treatment is essential for survival. Although open radical cystectomy is the gold standard
treatment for muscle-invasive, organ-confined bladder carcinoma, there is increasing interest
in laparoscopic radical cystectomy [24,25].
Radical cystectomy is also an optional or recommended treatment in high grade tumors like
T1G3 or Cis (table3) with high risk of progression and/or multiple recurrences after immuno‐
therapy (intravesical BCG) treatment [23].
Laparoscopic radical cystectomy could be divided in three times: 1, cystoprostatectomy in
males or cystectomy plus hysterectomy and ooforectomy in females; 2, lymphadenectomy and
3, urinary device reconstruction (intra or extracorporeal).
At this surgery it is necessary to have performed a correct selection criteria, including organ-
confined disease (≤T3), nonbulky limphadenopathy, absence of uncorrected coagulopathy,
body mass index < 35 kg/m2, non severe cardiorespiratory compromise and absence of prior
abdominal surgery or prior pelvic radiation therapy, because it has been shown that the
patients who do not meet these criteria have higher complication rates and poor profit of
lymphadenectomy [24].
About lymphadenectomy, there is strong evidence that the more nodes removed at cystecto‐
my, the better long-term survival time, so it is very important the extent of the lympadenec‐
tomy and the number of nodes removed. At laparosopic approach, it requires high-level
laparoscopic skills [24].
4.1.1. Morbidity and functional outcomes
General postoperative complications rate of open radical cystectomy vary between 30%-60% of
patients and the mortality is about 1.5%. At laparoscopic cystectomy the reported rates fall between
8%-42% and 1% of mortality, but these reports do not define blood transfusion as a complication
[24]. Nix et al. performed the only randomized controlled trial and reported no difference in
complications between open and laparoscopic approach, but the groups were too small [26]. Haber
et al. in their retrospectively series (n=50 in each group) showed an important benefit for the
laparoscopic approach and extracorporeal urinary diversion. These cases were associated with
reduced blood loss, decreased ileus, shorter hospital stay and no differences in operating time and
post-operative complications, and appear to have less postoperative analgesic requirements [27].
The indications or nerve-sparing cystectomy are limited to selected young patients with organ-
confined low-volume of tumor and extratrigonal location who are keen to maintain their sexual
potency. This preservation has rarely been analyzed and the series published lacked potency
data. Prostate-sparing radical cystectomy, another way to preserve erection, is controversial,
and there are no data about long-term oncological outcomes to validate their safety [27].
Regarding to urinary diversion, Haber et al. showed that the laparoscopic assisted urinary
diversion technique provides decreases in operating time, blood loss, transfusion rate, and more
rapid postoperative return to oral intake and ambulation, although major complications requiring
re-operation occurred more in this group than in the extracorporeal reconstruction [27].
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4.1.2. Oncologic outcomes
About surgical margins, both approaches obtained equivalent rates. The international
Laparoscopic Cystectomy Registry has been established a surgical margins rate of 2%,
compared to 1.6% for patients with organ-confined disease after open radical cystectomy [24,
27]. Chade et al. published an incidence of positive surgical margins ranged from 4-5% and
0-5% in open and laparoscopic approach respectively [25].
Lymphadenectomy plays an important role in oncological outcome. Published reports showed
an inferior average of nodal retrieval in laparoscopic procedure than in open approach. This
procedure strongly depends on the surgeon skills [25].
Local recurrence rates also appeared similar in both groups, around 7-10% [24]. Overall
survival published in the laparoscopic series was 90-100% at 1-2 years and 63-79% at 2-3 years
(selected cases), compared to open radical cystectomy series showing 62-68% at 5 years [25].
It is important to consider that the majority of published series had inadequate follow-up
periods or/and the laparoscopic and open cohorts were no identical (strong selection bias) [28].
Port-site recurrence seems rare with current laparoscopic techniques for placement of the
specimens into a laparoscopic bag, although there are few papers published on this topic.
Tanaka et al., for example, described one case of recurrence in a patient with a locally-advanced
stage (0.3%) [29].
4.1.3. Conclusions
Laparoscopic radical cystectomy is a difficult surgical technique specially to perform a correct
pelvic lymphadenectomy. Today it cannot be considered an alternative to open approach
because the postoperative series failed in selection criteria and follow-up period (not more
than 5 years). Multicentre prospective trials are needed.
Hand-assisted laparoscopic radical cystectomy has a less period of learning curve but it
decreases the advantages of a minimally invasive technique like pure laparoscopic cystectomy.
The extirpative component of laparoscopic cystectomy is well established. However laparo‐
scopic lymphadenectomy and reconstruction remains challenging, time-consuming, and
could be associated with major complications. Shorter number of cases demonstrated that it
is preferable to perform intracorporeal construction of the urinary diversion.
In conclusion, laparoscopic radical cystectomy with urinary diversion is a difficult procedure
that should be reserved for selected cases (localized bladder cancer) and performed by
experienced laparoscopic surgeons in selected centers.
4.2. Upper urinary tract urothelial cell cancer
Urothelial carcinomas are the fourth most common tumors after prostate (males) or breast
(females) cancer, lung cancer and colorectal cancer. They can be located in the upper urinary
tract (pyelocaliceal cavities and ureter). Upper urinary tract carcinomas are uncommon and
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account for only 5-10% of urothelial carcinomas. In 8-13% of patients, concurrent bladder
cancer is present [30].
Laparoscopic radical nephroureterectomy is reserved for localized disease (the tumor not
invades beyond peripelvic or periureteric fat or renal parenchyma). This technique must
comply with oncologic principles, which consists on preventing tumour seeding by avoiding
drilling the upper urinary tract during resection. The excision includes the distal ureter to avoid
recurrence. In the first experience there were reports of retroperitoneal metastatic or trocar
dissemination when locally-advanced tumors are manipulated [30]. Laparoscopic nephrour‐
eterectomy must take a place in a closed system, tumor morcelation should be avoided and an
endobag is necessary to extract the specimen (kidney and ureter removed en bloc with the
bladder cuff) [30].
Open and laparoscopic access seems to be equivalent in terms of efficacy and oncologic results,
but regarding to functional outcomes laparoscopy approach is superior to open surgery (as in
the laparoscopy nephrectomy). Laparoscopic approach resulted in less blood loss, shorter
hospital stay, decreased analgesic use, a shorter interval to oral intake, a decreased analgesic
use and a decrease interval to convalescence, with no significant difference in the rate of
perioperative complications [30,31].
Laparoscopy lymph node dissection associated with nephroureterectomy allows for optimal
staging and has a therapeutic purpose. However, the anatomic areas to perform it have not
yet clearly defined and it is not possible to standardize the indications to perform an extended
lymphadenectomy because the published data are retrospective [30].
Several reports analyzed retroperitoneoscopic nephroureterectomy; most of them found that
this approach was associated with longer operative times. However, blood loss, analgesic use,
and length of hospital stay were decreased in comparison to open approach [31].
In conclusion, laparoscopic nephroureterectomy is a feasible approach at localized upper
urinary tract tumors when it is impossible to perform a conservative treatment.
5. Testicular cancer
Testicular cancer represents between 1% and 1.5% of male neoplasms and 5% of urological
tumors in general. About 15-20% of stage I (no clinical node metastasis) seminoma and up to
30% of nonseminomatous germ cells cancer patients have subclinical metastases. Surgical
resection is the gold standard for managing postchemotherapy residual retroperitoneal tumor
mass cases [32,33].
Laparoscopic surgery in testicular cancer is focused on the treatment of residual retroperito‐
neal mass or lymph node metastasis after chemotherapy. Retroperitoneal lymph node
dissection is still a diagnostic and therapeutic option mainly in stage I disease [34,33].
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5.1. Morbidity and functional outcomes
Compared with open retroperitoneal lymph node dissection, laparoscopic approach, done by
expert hands, showed improvements in terms of analgesic requirements, complication rate
(15.6% Vs 33%), re-do surgery rate (1.4% Vs 6.6%) and hospital stay but laparoscopic approach
was associated with longer operating time [34-36].
Complication rates about laparoscopic approach varied between 5.6% and 46.7%. Major
intraoperative complications included bleeding and ureteral, duodenal and gallbladder injury.
In expert hands the vast of complications could be managed laparoscopically as low conversion
rates reported (1-5.4%). About retrograde ejaculation, a late complication, reports showed a
2-3% [34-36].
Retroperitoneal laparoscopic lymph node dissection was described by some authors. Results
showed its equivalence compared to conventional transperitoneal laparoscopic approach [37].
5.2. Oncologic outcome
Regarding stage I nonseminomatous germ cell tumor (any stage but not lymph node invasion
or metastasis), there were no differences between open and laparoscopic approach in terms of
retroperitoneal relapse, distant progression, biochemical failure and in-field relapse. There
were three reports of port-site metastasis (0.3%) in the literature. The rate of positive lymph
nodes was lower after laparoscopic approach. The need for secondary retroperitoneal surgery
did not differ (1.1-1.5%) and both groups showed similar cure rates (99.6%-100%) [34].
5.3. Conclusion
To justify laparoscopic approach instead of open surgery, laparoscopic retroperitoneal lymph
node dissection is a safe procedure with low complication rate and with perioperative
outcomes comparable with open surgery [35].
The consensus of the authors is that open or laparoscopic retroperitoneal lymph node dissec‐
tion should be concentrated in dedicated referral centers. Thus laparoscopic lymph node
resection might be indicated in: low-risk stages, if primary tumor contains mature teratoma
or if the primary nonseminomatous germ cell tumor is marker negative. Laparoscopic
retroperitoneal lymph node dissection represents a valuable tool for selected patients with
clinical stage I. Further studies should focus on the curative potential of the procedures as well
as on the role of post chemotherapy [33,34].
Laparoendoscopic single-site and natural orifice transluminal endoscopic in Urology onco‐
logic surgery. To minimize minimal invasive surgery.
Natural orifice transluminal endoscopic surgery (NOTES) and laparoendoscopic single-site
surgery (LESS) have been developed to reduce morbidity and scarring. NOTES uses existing
orifices of the human body to perform surgical or diagnostic techniques. The use of accessory
transabdominal ports as a part of evolution of NOTES is defined as hybrid NOTES. LESS
procedure implies only a single-port or a single-incision laparoscopy [38].
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LESS surgery was performed in several oncologic procedures, such a radical nephrectomy, radical
prostatectomy, nephroureterectomy and radical cystectomy. Cumulative series showing results
have been published. LESS has shown to be feasible (in expert hands) offering patient satisfac‐
tion and shortened convalescence applied to nephrectomy and radical prostatectomy. Patient
selection is the most important to minimizing complication and conversion rates [38].
Comparative series between conventional laparoscopy and LESS have been demonstrated that
there were only differences about cosmetic results when LESS was applied to perform radical
nephrectomy. Also, there were no differences concerning analgesia and hospital stay. So far,
all the comparative series fall to offer large number of cases, and they were retrospective and
norandomized [38].
About hybrid NOTES applied to oncologic surgery, the most commonly procedure performed
was transvaginal radical nephrectomy. Vaginal access was only used to insert a deflectable
camera, whereas two additional abdominal trocars were used as main working ports for
instrumentation. Currently, there are few papers with short number of cases and it requires
clinical and external validation [38].
LESS has proved to be immediately applicable in the clinical practicum, but requires a skilled
laparoscopic surgeon and well-selected patients. The current benefits of LESS are limited to
improve cosmetic results [39]. About NOTES, the question is whether women would prefer a
transvaginal access; there were studies published that showed a negative / neutral opinion of
nulliparous younger women, concerning about the effect of NOTES on sexual function [38,40].
In the future, it is important to perform a standard evaluation of cosmetic results, to design
prospective series combining LESS and NOTES as well as improving laparoscopic ergonomics
and instrumental [40].
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